Drawing for AKNEDERM

USPTO serial 79368504

AKNEDERM

Reviewed by CopyMark Law Group

Reg. 7464549Status 700Registered
Filing date
Status date
Registration date
Aug 6, 2024
Examiner
HUDSON, TAMARA BREE
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with AKNEDERM?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Deborah L. Shapiro

Deborah L. Shapiro Moses & Singer LLP405 Lexington AvenueThe Chrysler BuildingNew York, NY 10174

Goods and services

ClassDescriptionStatusFirst use
003Cosmetics, in particular cosmetic ointments and creams; non-medicated cosmetics and toiletry preparations; non-medicated cleansing preparations for the face and body; body oils for toilet purposes; face oils for toilet purposes; skin care preparations in the nature of balms, other than for medical purposesACTIVE—
005Pharmaceutical preparations and chemical substances for medical or pharmaceutical use for the treatment of acne; pharmaceutical preparations and chemical substances for medical or pharmaceutical use for the treatment of rosacea; pharmaceutical preparations and chemical substances for medical or pharmaceutical use for the treatment of skin disorders; plasters, materials for wound dressings for medical or pharmaceutical purposes; antiseptic preparations for health care; dietetic preparations adapted for medical use; food supplements, not for medical purposes, with a base of vitamins, minerals, trace elements, amino acids, vitamin preparations, in the form of granules, powders, emulsions, dragees, capsules, juices, sweets, dropsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Feb 15, 2025FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Feb 8, 2025OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Jan 30, 2025FICSFINAL DISPOSITION NOTICE SENT TO IB—
Jan 30, 2025FIMPFINAL DISPOSITION PROCESSED—
Jan 22, 2025OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Jan 22, 2025OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Nov 6, 2024FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Aug 6, 2024NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Aug 6, 2024R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
May 21, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
May 21, 2024PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 1, 2024NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Apr 16, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Apr 10, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Apr 10, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 10, 2024ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Apr 3, 2024GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Apr 3, 2024GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Apr 3, 2024CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Mar 22, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Mar 22, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 22, 2024TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 2, 2024RFNTREFUSAL PROCESSED BY IB—
Dec 11, 2023RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Dec 11, 2023RFRRREFUSAL PROCESSED BY MPU—
Dec 8, 2023RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Dec 7, 2023CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 7, 2023DOCKASSIGNED TO EXAMINER—
Sep 12, 2023CORRCORRECTION FROM IB ENTERED - NO REVIEW REQUIRED—
Aug 27, 2023CRCVCORRECTION TRANSACTION RECEIVED FROM IB—
May 2, 2023MAFRAPPLICATION FILING RECEIPT MAILED—
Apr 28, 2023NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 27, 2023REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance